| Display title | Chemistry:ANAVEX2-73 |
| Default sort key | ANAVEX2-73 |
| Page length (in bytes) | 8,570 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 817867 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>John Stpola |
| Date of page creation | 16:59, 26 May 2022 |
| Latest editor | imported>John Stpola |
| Date of latest edit | 16:59, 26 May 2022 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | ANAVEX2-73 is an experimental drug is in Phase II trials for Alzheimer's disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis, Parkinson's disease, Rett syndrome, stroke. ANAVEX2-73 acts as a muscarinic receptor and a moderate sigma1 receptor agonist. ANAVEX2... |
